3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Neoplasm Metastasis
2
von Hippel-Lindau Disease
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Thymus Neoplasms
1
Sarcoma, Kaposi
1
Sarcoma
1
Recurrence
1
Neuroendocrine Tumors
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Meningioma
1
Liposarcoma
1
Leiomyosarcoma
1
Kidney Neoplasms
1
Hamartoma Syndrome, Multiple
1
Glioma
1
Glioblastoma
1
Endometrial Neoplasms
1
Diffuse Intrinsic Pontine Glioma
1
Brain Neoplasms
1
Bone Neoplasms
1
Autistic Disorder
1
Astrocytoma
1
Advanced Lung Neuroendocrine Tumor
1
Interventions
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
trastuzumab deruxtecan
2
Cisplatin
2
Biopsy
2
pembrolizumab
1
luprolide acetate gel depot
1
entrectinib
1
dehydroftorafur
1
darolutamide
1
ceralasertib
1
apalutamide
1
amivantamab
1
Surveys and Questionnaires
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Platinum
1
Pemetrexed
1
Leuprolide
1
Immunoglobulin G
1
Gonadotropin-Releasing Hormone
1
Glutamate Carboxypeptidase II
1
Fluorouracil
1
Docetaxel
1
Disulfides
1
Carboplatin
1
Bevacizumab
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
Everolimus
×
30 days
×
Clear all
No trials found.